Digital50.com Category: Biotechnology

Immunosyn Corporation Files 10-Q

Fri, 16 May 2008 18:29:00 0500

LA JOLLA, Calif., May 16 PRNewswire-FirstCall — Immunosyn Corporation (OTC Bulletin Board: IMYN), a biotechnology firm that has obtained exclusive worldwide marketing, sales and distribution rights to the biopharmaceutical SF-1019 from its...

Former CMS Administrator: "'Blunt Instrument' Policies an Increasingly Bad Fit in Era of Personalized Health Care"

Fri, 16 May 2008 16:37:00 0500

ORLANDO, Fla., May 16 PRNewswire-FirstCall — Recent legislative emphasis on price negotiation and physician reimbursement as a means to reduce health care costs are nothing more than "short term patches" that hold no potential for truly reforming...

InterMune to Present at Citigroup Healthcare Conference

Fri, 16 May 2008 16:00:00 0500

BRISBANE, Calif., May 16 PRNewswire-FirstCall — InterMune, Inc. (Nasdaq: ITMN) today announced that John Hodgman, Senior Vice President and Chief Financial Officer of InterMune, will present at the Citigroup 2008 Global...

/C O R R E C T I O N -- Forest Laboratories, Inc./

Thu, 15 May 2008 13:22:00 0500

In the news release, Forest Laboratories, Inc. (NYSE: FRX) and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress, issued yesterday, May 15, by Forest Laboratories, Inc. over PR Newswire...

CorVel Corporation Announces Earnings Release Webcast

Fri, 16 May 2008 15:25:00 0500

IRVINE, Calif., May 16 PRNewswire-FirstCall — In conjunction with CorVel Corporation's (Nasdaq: CRVL) fiscal year earnings release, CorVel will be conducting a conference call that will be broadcast live over the Internet on Tuesday, June...

Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16

Fri, 16 May 2008 13:18:00 0500

WELLESLEY, Mass., May 16 PRNewswire — Xceed Molecular, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced that the company will feature its Ziplex Automated Gene-Expression System at Biomarker...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

Fri, 16 May 2008 12:50:00 0500

CAMBRIDGE, Mass., May 16 PRNewswire — Millennium Pharmaceuticals, The Takeda Oncology Company, today announced that new data from VELCADE clinical studies are scheduled to be featured at the 2008 American Society of Clinical Oncology (ASCO...

StemCyte Chief Scientific Officer to Present Company Overview with Focus on Indian Joint Venture at TiEcon 2008

Fri, 16 May 2008 12:40:00 0500

COVINA, Calif., May 16 PRNewswire — StemCyte Inc. today announced that Chief Scientific Officer Ram Bhat, Ph.D., will present a company overview with a focus on the StemCyte's Indian joint venture at the TiEcon 2008 conference in Santa...

Boston Scientific Announces FDA Approval of New Heart Failure Lead

Fri, 16 May 2008 12:33:00 0500

NATICK, Mass., May 16 PRNewswire-FirstCall — Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its ACUITY(R) Spiral left ventricular lead for use with cardiac resynchronization therapy...

Wyeth to Present at the 2008 Citi Investment Research Global Healthcare Conference

Fri, 16 May 2008 12:15:00 0500

MADISON, N.J., May 16 PRNewswire-FirstCall — Wyeth (NYSE: WYE) announced today that it will present at the 2008 Citi Investment Research Healthcare Conference on Wednesday, May 21, 2008 at 10:30 a.m. Eastern Time

Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting

Fri, 16 May 2008 12:02:00 0500

SOUTH SAN FRANCISCO, Calif., May 16 PRNewswire-FirstCall — Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that scientific collaborators will present results on HERmark(TM), the company's novel oncology assay, as a means to measure HER2...

Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day

Fri, 16 May 2008 12:00:00 0500

MONTVALE, N.J., May 16 PRNewswire-FirstCall — Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced progress with several key development programs at its R&D Day meeting with the investment community. The Company reported new clinical...

Chromatide and Novasep Have Extended Their Partnership to Develop Large Scale Solid Phase Peptide and Oligonucleotide Synthesis Technology.

Fri, 16 May 2008 11:54:00 0500

POMPEY, France, May 16 PRNewswire — Chromatide and Novasep have extended their partnership to develop large scale solid phase peptide and oligonucleotide synthesis technology. The resulting systems and equipment will meet the growing needs of...

CEO Addresses Fort Worth Business Leaders About Developing Pandemic and Business Continuity Plans

Fri, 16 May 2008 11:30:00 0500

FORT WORTH, Texas, May 16 PRNewswire — George Abercrombie, president and chief executive officer, Hoffmann-La Roche Inc., told more than 200 Fort Worth business leaders today at a Rotary Club of Fort Worth

Industry Executives Finding Value in Shift of Scientific Publications

Fri, 16 May 2008 11:27:00 0500

CHAPEL HILL, N.C., May 16 PRNewswire — The landscape of scientific publications strategy, planning and delivery is changing with the advent of transparency guidelines. Half of global publications groups are fully located in the marketing...

Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials

Fri, 16 May 2008 11:25:00 0500

NEW YORK, May 16 PRNewswire-FirstCall — Pulmo BioTech Inc. (OTC Bulletin Board: PLMO.OB) has announced details of the methodology and purpose of its Phase I Human Trials with its PulmoBind Molecular Imaging technology for the diagnosis of Pulmonary...

Boston Scientific's SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R)

Fri, 16 May 2008 11:00:00 0500

NATICK, Mass., May 16 PRNewswire-FirstCall — Boston Scientific Corporation (NYSE: BSX) today announced that results from an international, multi-center patient registry documenting the safety and clinical utility of the SpyGlass(R) Direct...

China Pharma Holdings, Inc. Donates Medicine for Sichuan Earthquake Relief

Fri, 16 May 2008 10:44:00 0500

NEW YORK and HAIKOU, China, May 16 Xinhua-PRNewswire-FirstCall — China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and brand bio-pharmaceutical products in...

Introducing Laboratory Evaluations for Integrative and Functional Medicine

Fri, 16 May 2008 10:07:00 0500

DULUTH, Ga., May 16 PRNewswire — Metametrix Institute ( http://www.metametrixinstitute.org ) announced today the publication of Laboratory Evaluations for Integrative and Functional...

Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results

Fri, 16 May 2008 09:08:00 0500

NEW BRUNSWICK, N.J., May 16 PRNewswire-FirstCall — Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) today reported financial results for the three months ended March 31, 2008.

Net loss for the...

CURE Magazine Announces Winner of 2008 Extraordinary Healer Award

Fri, 16 May 2008 09:00:00 0500

PHILADELPHIA, May 16 PRNewswire — CURE magazine announced the winner and finalists of its 2008 Extraordinary Healer Award for Oncology Nursing during a reception at the Oncology Nursing Society's (ONS) 33rd Annual Congress. Ortho Biotech Products...

Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease

Fri, 16 May 2008 09:00:00 0500

BALTIMORE, May 16 PRNewswire — Alba Therapeutics Corporation announced today that it has enrolled and randomized its first patient in a twelve-week Phase IIb trial with oral larazotide acetate, an inhibitor of intestinal barrier dysfunction, for...

Michael V. Novinski, Emisphere President/CEO Featured in the Wall Street Transcript

Fri, 16 May 2008 08:50:00 0500

CEDAR KNOLLS, N.J., May 16 PRNewswire-FirstCall — Highlighting the company's expectations for the future as well as its current product pipeline, Michael V. Novinski, President and CEO of Emisphere Technologies, Inc. (Nasdaq...

Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

Fri, 16 May 2008 08:30:00 0500

REHOVOT, Israel and JERSEY CITY, New Jersey, May 16 /PRNewswire-FirstCall/ — Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, today announced that it will present...

SemBioSys provides update on shrimp feed additive, Immunosphere(TM)

Fri, 16 May 2008 08:30:00 0500

CALGARY, May 16 PRNewswire-FirstCall - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that its joint development partner on the...

Campbell Alliance Sales Practice to Present Workshop at SPBT Annual Conference

Fri, 16 May 2008 08:30:00 0500

RALEIGH, N.C., May 16 PRNewswire — Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced that it will present a workshop at the Society of Pharmaceutical and Biotech...

Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings

Fri, 16 May 2008 08:30:00 0500

SAN CARLOS, Calif., May 16 PRNewswire-FirstCall — Nektar Therapeutics (Nasdaq: NKTR) announced initial results today from a Phase 1 study of NKTR- 102, PEGylated irinotecan. The data shows significant anti-tumor activity in patients with...

Catalyst Pharmaceutical Partners Reports First Quarter 2008 Financial Results

Fri, 16 May 2008 08:03:00 0500

CORAL GABLES, Fla., May 16 PRNewswire-FirstCall — Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the quarter ended March 31, 2008. The Company also announced the addition of Frank...

OncoGenex reports updated survival data on OGX-011 in a second-line chemotherapy trial for patients with prostate cancer